SOPHIRIS BIO INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Cash flows used in operating activities
Net loss for the period
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
Amortization of debt discount
Amortization of promissory note issuance costs
Depreciation of property and equipment
Amortization of premium/discount on securities available-for-sale
Change in fair value warrant liability
Noncash portion of loss on early extinguishment of debt
Payment of original issue discount
Foreign exchange transaction loss
Other

Changes in operating assets and liabilities:
Other receivables
Prepaid expenses
Prepaid expenses and other current assets
Accounts payable
Accrued expenses
Net cash used in operating activities
Cash flows provided by (used in) investing activities
Purchases of property and equipment
Maturity of securities available-for-sale
Purchases of securities available-for-sale
Net cash provided by (used in) investing activities
Cash flows provided by financing activities
Issuance of common shares under stock purchase agreement, net of issuance cost
Proceeds from the exercise of warrants
Proceeds from exercise of stock options
Payment of issuance costs in connection with public offering
Proceeds from the issuance of the Silicon Valley Bank promissory note, net of issuance costs
Principal payments on the Oxford promissory notes
Net cash provided by financing activities
Effect of exchange rate changes on cash and cash equivalents
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period

Supplemental disclosures of cash flow information
Cash paid for interest
Supplemental disclosures of non-cash investing and financing activities
Valuation of warrant liability upon issuance of warrants
Reclassification of fair value of warrant liability to equity as a result of the amendment of the underlying common share purchase warrants
Value of warrants issued in connection with the Silicon Valley Bank promissory note
Valuation of exercised warrants reclassified from warrant liability to contributed surplus
Change in the fair value of stock-based compensation liability recorded to contributed surplus
Unrealized loss on securities available-for sale
Issuance costs included in accounts payable and accrued expenses but not paid

Comments